Clover Health Investments, Corp. filings document the company’s Medicare Advantage insurance business, physician enablement technology, operating results, governance, and material events. Recent 8-K reports furnish earnings releases, guidance updates, Medicare Advantage enrollment information, Regulation FD presentations, and supplemental shareholder Q&A materials related to financial performance and business priorities.
Proxy materials cover annual meeting matters, board and governance disclosures, executive compensation, equity awards, and related stockholder voting items. Other current reports document officer transitions, principal financial and accounting officer appointments, compensatory arrangements, and formal disclosures connected to the company’s remote-first corporate structure and public-company reporting obligations.
Clover Health Investments director Anna U. Loengard reported an equity grant and updated share holdings. On January 6, 2026, she acquired 79,365 shares of Class A Common Stock at $0, representing time-based restricted stock units that will vest in full on the first anniversary of January 6, 2026, if she continues to serve as a director through that date. Following this award, she beneficially owns 527,456 Class A shares directly. She also reports indirect beneficial ownership of 27,600 Class A shares held in a custodial IRA for her son and 29,610 Class A shares held in a custodial IRA for her daughter, for which she serves as custodian.
Clover Health Investments, Corp. director William G. Robinson Jr reported an equity award of 79,365 shares of Class A common stock on January 6, 2026. These shares represent time-based restricted stock units that will vest in full on the first anniversary of January 6, 2026, as long as he continues to serve as a director through that date. The award was recorded at a price of $0 per share, reflecting a grant rather than an open-market purchase. After this grant, Robinson beneficially owned a total of 597,987 shares of Class A common stock in direct ownership.
Clover Health Investments, Corp. director Thomas L. Tran reported an equity award of Class A Common Stock. On January 6, 2026, he was granted 79,365 shares of Class A Common Stock, received as time-based restricted stock units (RSUs) at a price of $0 per share, meaning this was a compensatory grant rather than an open-market purchase.
According to the filing, these RSUs represent shares that will vest in full on the first anniversary of January 6, 2026, as long as Tran continues to serve as a director through that vesting date. After this award, Tran beneficially owns 180,029 shares of Class A Common Stock directly. This filing reflects routine director compensation in the form of equity.
Clover Health Investments, Corp. executive Jamie L. Reynoso, CEO for Medicare Advantage, reported a small insider sale of Class A common stock. On January 7, 2026, Reynoso sold 2,102 shares at a weighted average price of $2.53 per share in an open-market transaction. The sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on March 13, 2025, which automates trades according to preset instructions. After this transaction, Reynoso directly beneficially owned 2,757,029 shares of Clover Health Class A common stock.
An insider of CLOV has filed a Form 144 indicating an intent to sell 2,102 shares of common stock through broker Morgan Stanley Smith Barney LLC on or about January 7, 2026 on the NASDAQ. These shares were acquired on January 3, 2026 as restricted stock units from the issuer. The filing notes that 424,304,898 common shares were outstanding. Over the prior three months, the same seller completed additional common stock sales labeled as “10b5-1 Sales”.
Clover Health Investments, Corp. insider Jamie L. Reynoso, who serves as CEO, Medicare Advantage, reported a small open-market sale of company stock. On 12/18/2025, Reynoso sold 4,913 shares of Class A common stock at a weighted average price of $2.61 per share, with individual trade prices ranging from $2.58 to $2.64. The transaction was executed under a pre-established Rule 10b5-1 trading plan adopted on March 13, 2025, which is designed to allow insiders to sell shares according to a preset schedule. After this sale, Reynoso beneficially owns 2,767,240 shares of Class A common stock, held in direct form.
Clover Health Investments, Corp.'s CEO for Medicare Advantage reported automatic share withholding transactions related to restricted stock unit vesting.
On December 14, 2025 and December 15, 2025, 12,567 and 8,691 shares of Class A Common Stock, respectively, were withheld at $2.7 per share to cover tax obligations when 6.25% quarterly tranches of time-based RSU grants from March 14, 2022 and September 16, 2022 vested. After these transactions, the officer directly beneficially owns 2,772,153 shares of Class A Common Stock, and the remaining RSUs continue to vest quarterly in 6.25% installments through March 14, 2026 and September 15, 2026, subject to continued service.
Clover Health Investments, Corp. reported an insider share withholding related to restricted stock vesting. On December 14, 2025, an officer serving as CEO, Counterpart Health had 98,411 shares of Class A common stock automatically withheld at $2.7 per share to cover tax obligations when a portion of previously granted restricted stock units vested.
After this transaction, the reporting person beneficially owned 1,051,674 Class A shares directly and 1,610,482 shares indirectly through a trust. The withheld shares correspond to 6.25% of the original time-based RSU grant made on March 14, 2022, which continues to vest in equal 6.25% quarterly installments through March 14, 2026, subject to continued service.
Clover Health Investments, Corp. reported an insider equity transaction by an officer serving as General Counsel & Secretary. On December 15, 2025, 6,404 shares of Class A common stock were withheld to cover tax obligations triggered by the vesting of time-based restricted stock units (RSUs).
The withheld shares correspond to 6.25% of the original RSU grant made on September 15, 2022. The remaining RSUs are scheduled to vest quarterly in equal 6.25% installments, with a final vesting date on September 15, 2026, subject to the reporting person’s continued service. Following this tax-withholding event, the reporting person beneficially owns 1,222,365 Class A shares directly.
Clover Health Investments Corp. insider tax withholding transaction
A Clover Health Investments Corp. officer, serving as General Counsel and Secretary, reported an automatic share withholding related to restricted stock units. On November 14, 2025, 7,459 shares of Class A common stock were withheld at a price of $2.47 per share to cover tax obligations triggered by the vesting of time-based restricted stock units granted on February 14, 2022. After this transaction, the reporting person beneficially owned 1,228,769 shares of Class A common stock. The underlying restricted stock units vest in quarterly installments of 6.25%, with the final vesting date scheduled for February 14, 2026, conditioned on continued service.